{"id":2199,"date":"2026-07-31T21:36:48","date_gmt":"2026-07-31T21:36:48","guid":{"rendered":"https:\/\/lavoz.us.com\/homepage\/?p=2199"},"modified":"2026-07-31T21:36:48","modified_gmt":"2026-07-31T21:36:48","slug":"glp-1-boom-raises-new-questions","status":"publish","type":"post","link":"https:\/\/lavoz.us.com\/homepage\/uncategorized\/glp-1-boom-raises-new-questions\/","title":{"rendered":"GLP-1 boom raises new questions"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong><em>Experts weigh long-term risks, access barriers, and pediatric concerns over obesity drugs<\/em><\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nearly 29 million Americans are currently taking GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound, transforming obesity and Type 2 diabetes treatment. But as prescriptions continue to rise, medical experts say critical questions remain about how long patients should stay on the drugs, who can access them, and what their long-term effects could be, particularly for children and adolescents.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Weight loss benefits come with long-term uncertainties<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Dr. Jena Shaw Tronieri, senior research investigator at the University of Pennsylvania&#8217;s Center for Weight and Eating Disorders, presented new findings showing that semaglutide continues to reduce calorie intake even after patients report the return of hunger or &#8220;food noise.&#8221; Her research suggests that while weight loss eventually plateaus, the medication still helps patients maintain lower food consumption over time.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">She warned, however, that discontinuing treatment often leads to significant weight regain. Studies show that roughly half of patients stop taking GLP-1 medications within a year, and many regain about two-thirds of the weight they initially lost. According to Tronieri, patients should be counseled that these medications are generally intended for long-term management, similar to treatments for other chronic conditions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Children and access remain major concerns<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">While GLP-1 medications have been approved for adolescents with obesity, Dr. Dan Cooper, professor emeritus of pediatrics at UC Irvine, urged caution when prescribing them during childhood and adolescence. He said researchers still do not fully understand how long-term use may affect developing muscles, bones, and brain function during critical stages of growth.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cooper also argued that medications should never replace comprehensive lifestyle interventions. Expanding physical education programs, improving access to recreational spaces, and promoting healthy habits, particularly in underserved communities, remain essential components of addressing childhood obesity.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Cost keeps treatment out of reach<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Harvard Medical School professor Dr. Fatima Cody Stanford emphasized that access, not supply, has become the greatest challenge. Although medication shortages have eased, many patients who would benefit the most still cannot afford treatment, with retail prices often ranging from <strong>$900 to $1,300 per month<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">She also highlighted persistent racial and socioeconomic disparities in obesity care, arguing that administrative hurdles, insurance restrictions, and uneven Medicaid policies continue to limit access for many low-income communities. While the recently launched Medicare GLP-1 Bridge Program lowers costs for eligible beneficiaries, Stanford cautioned that prior authorization requirements and state-level differences could continue to widen existing healthcare inequities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The panel concluded that GLP-1 medications have fundamentally changed obesity treatment, but experts agreed they are not a standalone solution. Long-term research, equitable access, and sustained lifestyle support will be critical as millions of Americans continue turning to these therapies.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n\n<h1 class=\"wp-block-heading\">Boom de los GLP-1 abre nuevas dudas<\/h1>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><em>Expertos analizan riesgos, acceso y efectos a largo plazo de estos medicamentos<\/em><\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cerca de 29 millones de estadounidenses utilizan actualmente medicamentos GLP-1 como Ozempic, Wegovy, Mounjaro y Zepbound, f\u00e1rmacos que han transformado el tratamiento de la obesidad y la diabetes tipo 2. Sin embargo, a medida que su uso contin\u00faa creciendo, especialistas advierten que a\u00fan persisten interrogantes sobre cu\u00e1nto tiempo deben utilizarse, qu\u00e9 ocurre cuando los pacientes los suspenden y cu\u00e1les podr\u00edan ser sus efectos a largo plazo, especialmente en ni\u00f1os y adolescentes.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Los beneficios para perder peso conviven con interrogantes a largo plazo<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">La Dra. Jena Shaw Tronieri, investigadora principal del Centro para los Trastornos del Peso y la Alimentaci\u00f3n de la Universidad de Pensilvania, present\u00f3 nuevos hallazgos que muestran que la semaglutida contin\u00faa reduciendo la ingesta cal\u00f3rica incluso cuando los pacientes vuelven a experimentar hambre o el denominado &#8220;ruido alimentario&#8221;. Su investigaci\u00f3n indica que, aunque la p\u00e9rdida de peso tiende a estabilizarse con el tiempo, el medicamento sigue ayudando a mantener un menor consumo de alimentos.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">No obstante, advirti\u00f3 que abandonar el tratamiento suele provocar una recuperaci\u00f3n importante del peso perdido. Diversos estudios muestran que aproximadamente la mitad de los pacientes deja de utilizar estos medicamentos durante el primer a\u00f1o y que muchos recuperan cerca de dos tercios del peso que hab\u00edan perdido. Por ello, se\u00f1al\u00f3 que los pacientes deben comprender que estos tratamientos est\u00e1n dise\u00f1ados para un uso prolongado, al igual que otros medicamentos destinados a controlar enfermedades cr\u00f3nicas.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>El uso en menores y el acceso generan preocupaci\u00f3n<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Aunque algunos medicamentos GLP-1 ya est\u00e1n aprobados para adolescentes con obesidad, el Dr. Dan Cooper, profesor em\u00e9rito de Pediatr\u00eda de la Universidad de California en Irvine, pidi\u00f3 cautela al prescribirlos durante la infancia y la adolescencia. Explic\u00f3 que todav\u00eda no se conoce con certeza c\u00f3mo podr\u00edan afectar el desarrollo de m\u00fasculos, huesos y cerebro en una etapa clave para el crecimiento.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El especialista tambi\u00e9n sostuvo que estos medicamentos no deben reemplazar las intervenciones intensivas sobre el estilo de vida. A su juicio, mejorar la educaci\u00f3n f\u00edsica en las escuelas, ampliar el acceso a espacios recreativos y promover h\u00e1bitos saludables, especialmente en comunidades de menores recursos, sigue siendo una estrategia indispensable para enfrentar la obesidad infantil.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>El costo sigue siendo la mayor barrera<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">La Dra. Fatima Cody Stanford, profesora de Medicina y Pediatr\u00eda de la Escuela de Medicina de Harvard, afirm\u00f3 que el principal problema ya no es la disponibilidad de los medicamentos, sino su accesibilidad. Aunque la escasez registrada en a\u00f1os anteriores ha disminuido, muchos pacientes que podr\u00edan beneficiarse de estos tratamientos no pueden costearlos, ya que sus precios pueden oscilar entre <strong>US$900 y US$1.300 mensuales<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Adem\u00e1s, destac\u00f3 que persisten importantes desigualdades raciales y socioecon\u00f3micas en el acceso a la atenci\u00f3n de la obesidad. Seg\u00fan explic\u00f3, los requisitos administrativos, las restricciones de los seguros m\u00e9dicos y las diferencias entre los programas estatales de Medicaid contin\u00faan limitando el acceso de las comunidades de menores ingresos. Si bien el nuevo programa Medicare GLP-1 Bridge busca reducir el costo para algunos beneficiarios elegibles, Stanford advirti\u00f3 que los procesos de autorizaci\u00f3n previa y las diferencias entre estados podr\u00edan mantener las brechas existentes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Los especialistas coincidieron en que los medicamentos GLP-1 representan uno de los mayores avances recientes en el tratamiento de la obesidad. Sin embargo, subrayaron que no constituyen una soluci\u00f3n aislada y que su \u00e9xito depender\u00e1 de una combinaci\u00f3n de investigaci\u00f3n a largo plazo, acceso equitativo y programas sostenidos de alimentaci\u00f3n saludable, actividad f\u00edsica y seguimiento m\u00e9dico.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Experts weigh long-term risks, access barriers, and pediatric concerns over obesity drugs. Nearly 29 million Americans are currently taking GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound, transforming obesity and Type 2 diabetes treatment. But as prescriptions continue to rise, medical experts say critical questions remain about how long patients should stay on the [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":2200,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2199","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/lavoz.us.com\/homepage\/wp-json\/wp\/v2\/posts\/2199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lavoz.us.com\/homepage\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lavoz.us.com\/homepage\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lavoz.us.com\/homepage\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/lavoz.us.com\/homepage\/wp-json\/wp\/v2\/comments?post=2199"}],"version-history":[{"count":1,"href":"https:\/\/lavoz.us.com\/homepage\/wp-json\/wp\/v2\/posts\/2199\/revisions"}],"predecessor-version":[{"id":2201,"href":"https:\/\/lavoz.us.com\/homepage\/wp-json\/wp\/v2\/posts\/2199\/revisions\/2201"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lavoz.us.com\/homepage\/wp-json\/wp\/v2\/media\/2200"}],"wp:attachment":[{"href":"https:\/\/lavoz.us.com\/homepage\/wp-json\/wp\/v2\/media?parent=2199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lavoz.us.com\/homepage\/wp-json\/wp\/v2\/categories?post=2199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lavoz.us.com\/homepage\/wp-json\/wp\/v2\/tags?post=2199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}